相关实验视频

Updated: Jul 5, 2025

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

临床试验可以快速预测细菌对单克隆抗体治疗的敏感性

Matthew J Slarve¹, Neven Bowler¹, Elizabeth Burk¹

¹Department of Molecular Microbiology and Immunology, University of Southern California, Los Angeles, California, USA.

|January 23, 2024

概括

现在新的测定方法可以预测单克隆抗体 (MAbs) 是否能有效地治疗像Acinetobacter baumannii这样的耐药细菌引起的感染,从而有助于开发这些有前途的疗法.

科学领域:

微生物学微生物学
免疫学免疫学免疫学
临床诊断临床诊断临床诊断

背景情况:

抗菌素耐药性 (AMR) 构成了全球健康的重大威胁.
单克隆抗体 (MAbs) 是对抗AMR感染的有希望的治疗策略.
缺乏验证的试验阻碍了针对特定病原体的MAbs的临床开发.

研究的目的:

建立和验证针对抗Acinetobacter baumannii单克隆抗体 (MAbs) 的简单临床敏感性测定.
预测MAbs对特定病原菌株的体内疗效.
促进针对微生物表面的MAbs的临床开发和部署.

主要方法:

开发和验证两种敏感性测定:流动细胞计和乳珠凝结.
测试了一种新型和三种现有的反阿药物. 宝曼尼的马布斯.
临床前模型用于将检测结果与体内结果相关联.

主要成果:

开发的试验显示出高灵敏度,特异性和可重复性.
建立了明确的敏感性断点,准确预测体内疗效或失败.
测试成功确定了对测试的抗A的敏感性/耐药性. 宝曼尼的马布斯.

结论:

对于Acinetobacter baumannii,已经成功建立和验证了简单的MAb敏感性测试.
这些测试可以预测MAb的疗效,从而使得得知情的临床决策.
这些试验有可能促进对抗微生物感染的MAbs的临床开发.

关键词:

细菌感染细菌感染传染病传染病传染病传染病

更多相关视频

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Published on: September 10, 2018

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

相关概念视频